Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
359
datasets available to search
ShareScore release 0.9.0
Dataset results
359 results for “indole”
Figure 1 in Effects of Indole-3-Butyric Acid (IBA) and rooting media on rooting and survival of air layered wax apple (Syzygium samarangense) CV Jambu Madu
Figure 1. Effects of different rooting media and various concentrations of IBA on the rooting of wax apple air layers. M C: Sphagnum 1 0 moss (wet) + IBA 0 mg L-1, M C: Vermicompost + IBA 0 mg L-1, M C: Garden soil + IBA 0 mg L-1, M C: Sphagnum moss (wet) + 2 0 3 0 1 1 IBA 1000 mg L-1, M C: Vermicompost + IBA 1000 mg L-1, M C: Garden soil + IBA 1000 mg L-1, M C: Sphagnum moss (wet) + IBA 2 1 3 1 1 2 1500 mg L-1, M C: Vermicompost + IBA 1500 mg L-1, M C: Garden soil + IBA 1500 mg L-1, M C: Sphagnum moss (wet) + IBA 2000 mg 2 2 3 2 1 3 L-1, M C : Vermicompost + IBA 2000 mg L-1 and M C : Garden soil + IBA 2000 mg L-1.
Figure 3 in Effects of Indole-3-Butyric Acid (IBA) and rooting media on rooting and survival of air layered wax apple (Syzygium samarangense) CV Jambu Madu
Figure 3. Survival rate of air layers (%) of wax apple as affected by different concentrations of IBA and growing media after detaching from mother plants. M C: Sphagnum moss (wet) + IBA 1000 mg L-1, M C: Vermicompost + IBA 1000 mg L-1, M C: Garden soil + IBA 1 1 2 1 3 1 1000 mg L-1, M C: Sphagnum moss (wet) + IBA 1500 mg L-1, M C: Vermicompost + IBA 1500 mg L-1, M C: Garden soil + IBA 1500 mg L-1, 1 2 2 2 3 2 M C : Sphagnum moss (wet) + IBA 2000 mg L-1, M C : Vermicompost + IBA 2000 mg L-1 and M C : Garden soil + IBA 2000 mg L-1.
Figure 2 in Effects of Indole-3-Butyric Acid (IBA) and rooting media on rooting and survival of air layered wax apple (Syzygium samarangense) CV Jambu Madu
Figure 2. Effects of IBA hormones and different rooting media on the survivability of rate of wax apple air layered. M 1 C 0: Sphagnum moss (wet) + IBA 0 mg L-1, M C: Vermicompost + IBA 0 mg L-1, M C: Garden soil + IBA 0 mg L-1, M C: Sphagnum moss (wet) + IBA 2 0 3 0 1 1 1000 mg L-1, M C: Vermicompost + IBA 1000 mg L-1, M C: Garden soil + IBA 1000 mg L-1, M C: Sphagnum moss (wet) + IBA 1500 mg L-1, 2 1 3 1 1 2 M C: Vermicompost + IBA 1500 mg L-1, M C: Garden soil + IBA 1500 mg L-1, M C: Sphagnum moss (wet) + IBA 2000 mg L-1, M C: 2 2 3 2 1 3 2 3 Vermicompost + IBA 2000 mg L-1 and M C: Garden soil + IBA 2000 mg L-1. Bars represent means (n = 7) ± standard error (S.E.). a, b, and 3 3 c indicate significant differences within each growth period (p <0.05).
X-ray diffraction data set for PDB 9G3L: LecB from PA01 in complex with beta-fucosylamide-indole derivative
<p>X-ray diffraction images collected on proxima 1 Soleil the 7th of march 2024 at SOLEIL synchrotron, Saint Aubin, France for PDB ID 9G3L using a DECTRIS EIGER X 16M detector. X-ray dataset and xdsme processing for the structure of LecB from <em>Pseudomonas aeruginosa</em> PA01 strain in complex with synthetic beta-fucosylamide-indole derivative. Images 1-900 were removed during processing and resolution was cut to 1.74 angstrom.</p>
Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen synthase kinase-3β inhibitors
<p>The dataset related to the publication:</p> <p>Andreev et al. Design, Synthesis and Biological Evaluation of 7 Chloro-9H-pyrimido[4,5-b]indole-based Glycogen synthase kinase-3β inhibitors.<br> <br> The files include:</p> <p>1) Movies of the MD simulations of compounds 14b (<strong>Cmpd14b.mpg</strong>) and 24 (<strong>Cmpd24.mpg</strong>).</p> <p>2) Raw trajectory files of the Desmond MD simulations of the compounds 14b (<strong>14b.zip</strong>), 24 (<strong>24.zip</strong>) and 24 (3a<em>R</em>, 7a<em>S</em>) (<strong>24_3aR_7aS.zip</strong>) (contains out.cms and the full trj files).</p> <p>3) Output conformations of the QM Tautomer & Conformation Predictor of Maestro (Schrödinger, LLC, New York, NY, 2019) of the compounds<br> 14b (<strong>Cmpd14b_QMconftauto_output.mae</strong>; <strong>Cmpd14b_QMconftauto_output.sdf</strong>), <br> 24 (<strong>Cmpd24_QMconftauto_output.mae</strong>; <strong>Cmpd24_QMconftauto_output.sdf</strong>) and <br> 24 (3a<em>R</em>, 7a<em>S</em>) (<strong>Cmpd24_3aR_7aS_QMconftauto_output.mae</strong>; <strong>Cmpd24_3aR_7aS_QMconftauto_output.sdf</strong>)</p> <p>4) Jaguar pKa calculation (conformations) output-files for compounds 14b, 14c, 14d, 14e, 14f, 14g, 14h, 14i, 14j, 14k, 14l, 14m, 14n <strong>pKa.zip</strong> (contains conformation in .mae file and Final weighted pKa value in .out file).</p>
Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy
ClinicalTrials.gov study NCT01077518. IPD Sharing: YES. Countries: 17. Publications: 1.
Integrated multi-omics analysis of early lung adenocarcinoma links tumor biological features with predicted indolence or aggressiveness
<p>This is a collection of datasets presented in the manuscript "Multi-omics data analysis identifies correlations between tumor biology features and predicted behaviors in early lung adenocarcinoma". This study provides a comprehensive profiling of LUAD indolence and aggressiveness at the biological bulk and single cell levels, as well as at the clinical and radiomics levels. This hypothesis generating study uncovers several potential future research avenues. It also highlights the importance and power of data integration to improve our systemic understanding of LUAD and to help reduce the gap between basic science research and clinical practice.</p>
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT03078855. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
ClinicalTrials.gov study NCT01059630. IPD Sharing: Not stated. Countries: 14. Publications: 4.
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
ClinicalTrials.gov study NCT02626455. IPD Sharing: NO. Countries: 35. Publications: 2.
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT01316523. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
ClinicalTrials.gov study NCT03520920. IPD Sharing: YES. Countries: 1. Publications: 0.
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
ClinicalTrials.gov study NCT01660451. IPD Sharing: NO. Countries: 25. Publications: 3.
Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
ClinicalTrials.gov study NCT01200589. IPD Sharing: Not stated. Countries: 16. Publications: 1.
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
ClinicalTrials.gov study NCT01938001. IPD Sharing: Not stated. Countries: 17. Publications: 2.
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT02339922. IPD Sharing: NO. Countries: 1. Publications: 1.
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT01995669. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma
ClinicalTrials.gov study NCT00635154. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
ClinicalTrials.gov study NCT01282424. IPD Sharing: YES. Countries: 6. Publications: 3.
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
ClinicalTrials.gov study NCT03105336. IPD Sharing: YES. Countries: 2. Publications: 14.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.